Amgen Inc - AMGN STOCK NEWS

Amgen (NASDAQ: AMGN) has announced its participation in the 35th Annual Oppenheimer Healthcare Life Sciences Conference scheduled for Wednesday, February 12, 2025, at 11:20 a.m. ET. Narimon Honarpour, senior vice president of global development at Amgen, will represent the company at the conference.

The presentation will be accessible through a live webcast simultaneously available to investors, news media, and the general public. The webcast can be accessed through Amgen's website (www.amgen.com) under the Investors section, along with other management presentations from investor and medical conferences. The presentation will remain archived and available for replay on the website for a minimum of 90 days following the event.

Amgen (NASDAQ:AMGN) reported strong financial results for Q4 and full year 2024. Q4 total revenues increased 11% to $9.1 billion, with product sales growing 11% driven by 14% volume growth. Full-year revenues rose 19% to $33.4 billion, with product sales up 19% driven by 23% volume growth.

Ten products achieved double-digit sales growth in Q4, including Repatha, BLINCYTO, TEZSPIRE, EVENITY, and TAVNEOS. The company's rare disease portfolio contributed $1.2 billion in Q4 sales. Q4 GAAP EPS decreased 18% to $1.16, while non-GAAP EPS increased 13% to $5.31. Full-year GAAP EPS declined 39% to $7.56, while non-GAAP EPS grew 6% to $19.84.

The company generated record free cash flow of $10.4 billion for the full year, compared to $7.4 billion in 2023, driven by business performance and improved working capital management.

Amgen (AMGN) has announced it will release its fourth quarter and full year 2024 financial results on Tuesday, February 4, 2025, after U.S. market close. The company will host a conference call with the investment community at 4:30 p.m. ET, featuring Chairman and CEO Robert A. Bradway along with other senior management team members.

The conference call will be broadcast live via webcast and will be accessible to media, investors, and the general public through Amgen's website. The webcast will remain available for replay for at least 90 days following the event.

deCODE genetics, an Amgen subsidiary, has achieved a significant breakthrough by creating the first complete recombination map of the human genome, published in Nature. The research provides important insights into how DNA is mixed during reproduction, marking a major advancement in understanding genetic diversity and its impact on health and fertility.

The groundbreaking map includes previously difficult-to-detect shorter-scale shuffling of grandparental DNA and identifies areas devoid of major reshuffling. This research helps explain why some pregnancies fail and how the genome maintains a balance between diversity and stability. The study reveals important gender differences in recombination patterns, noting that women experience increased frequency of non-crossover recombinations with age, potentially explaining higher pregnancy risks in older mothers.

This advancement is particularly relevant for fertility research, as recombination errors can lead to serious reproductive issues affecting approximately one in ten couples worldwide. The study also demonstrates that mutations are elevated near DNA mixing regions, providing new understanding of human evolution and individual health outcomes.

Amgen (NASDAQ:AMGN) has received FDA approval for LUMAKRAS® (sotorasib) in combination with Vectibix® (panitumumab) for treating adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC). The approval is based on the Phase 3 CodeBreaK 300 study results.

The study showed that LUMAKRAS (960 mg daily) plus Vectibix demonstrated a median progression-free survival of 5.6 months compared to 2 months with standard care, and an overall response rate of 26% versus 0%. The KRAS G12C mutation occurs in approximately 3-5% of colorectal cancers.

The most common adverse reactions (≥20%) include rash (87%), dry skin (28%), diarrhea (28%), stomatitis (26%), fatigue (21%), and musculoskeletal pain (21%).

Amgen (NASDAQ:AMGN) has announced its participation in the 2025 J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 3:00 p.m. PT, featuring Robert A. Bradway, chairman and chief executive officer of Amgen.

The event will be accessible through a live webcast simultaneously available to investors, news media, and the general public. The presentation can be accessed through Amgen's website (www.amgen.com) under the Investors section, along with other selected management presentations from investor and medical conferences. The webcast recording will remain available for replay for a minimum of 90 days following the event.

Asher Biotherapeutics has entered into a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate the combination of etakafusp alfa (AB248) with IMDELLTRA® (tarlatamab) in patients with extensive-stage small cell lung cancer (ES-SCLC).

The collaboration will focus on testing Asher Bio's CD8+ T cell targeted interleukin-2 immunotherapy alongside Amgen's DLL3-targeting Bispecific T-cell Engager therapy. Amgen will sponsor and conduct a global Phase 1b study to evaluate the safety and early efficacy of the combination therapy. Asher Bio will maintain full ownership of etakafusp alfa and provide it to Amgen at no cost.

Amgen (NASDAQ:AMGN) has announced its quarterly dividend for the first quarter of 2025. The company's Board of Directors has declared a dividend of $2.38 per share. Shareholders who are recorded as stockholders by the close of business on February 14, 2025, will receive the dividend payment on March 7, 2025.

Amgen's BLINCYTO (blinatumomab) has shown significant improvement in disease-free survival when added to chemotherapy for newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). In a Phase 3 study, the three-year disease-free survival rate was 96.0% for patients receiving BLINCYTO plus chemotherapy, compared to 87.9% for chemotherapy alone, representing a 61% reduction in disease relapse risk.

The study met its primary endpoint early, leading to early termination of randomization due to clear benefits. For standard-risk average patients, three-year survival was 97.5% with BLINCYTO versus 90.2% with chemotherapy alone. For high-risk patients, rates were 94.1% versus 84.8%. Safety results aligned with BLINCYTO's known profile, showing minimal severe side effects.